Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.

CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.

Australia’s CSL has probably made the right decision to settle a price-fixing lawsuit in the United States and thereby avoid a protracted legal battle that could have seen further substantial legal costs even if it eventually won. But the proposed settlement has some analysts concerned the legal basis for the lawsuit was thin as it stemmed from regulatory questions raised in a failed industry merger.